The immune system, which is indispensible for controlling neoplasias, relies on its innate and acquired
immunity components to mount an effective response against tumors. In this context, dendritic cells (DCs) are seen as the
best antigen-presenting cells because of their capacity for cross-presentation, which can activate both T-helper and
cytotoxic lymphocytes. Thus immunotherapy with DCs is considered promising, especially for early-stage cancers. This
article provides a clarifying review of recent perspectives on the development of cancer immunotherapy, which has a wide
potential for therapeutic applications, and of patents related to immunotherapy with DCs.